Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trilipix CV Outcomes Study To Focus On Patients With High Triglycerides, Low HDL-Cholesterol

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA follows its advisory committee’s recommendation and requires a post-marketing study of Abbott’s fibrate to determine whether combination use with a statin provides a cardiovascular benefit over statin monotherapy in high-risk patients.

Advertisement

Related Content

ANCHOR Indication For Amarin’s Vascepa Will Face FDA Panel Scrutiny
Trilipix Advisory Committee Call For Outcomes Trial Could Be Damaged By Niaspan Failure
Could ACCORD Results Mean Another Trial For Trilipix?
Trilipix Use In Diabetics Might Be Restricted After FDA Panel Review Of ACCORD Data
Abbott's Fibrate Franchise Will Likely Remain Limited To High-Risk Patients After ACCORD

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel